Nxera Pharma Partners with Shionogi to Advance QUVIVIQ™ in Japan
Nxera Pharma Partners with Shionogi to Advance QUVIVIQ™ in Japan
QUVIVIQ™ has emerged as a potential leading treatment option within the class of dual orexin antagonists, specifically targeting sleep disorders like insomnia. This innovative approach holds great promise for improving patient outcomes.
Recently, Nxera Pharma Co., Ltd. (formerly known as Sosei Group or Sosei Heptares) announced an exciting new commercial partnership with Shionogi & Co., Ltd. The agreement was facilitated through Nxera Pharma Japan Co., Ltd. (NPJ), which will henceforth rely on Shionogi for the distribution and sales of QUVIVIQ™. This strategic move comes after terminating an earlier partnership with Mochida Pharmaceutical Co., Ltd., allowing Shionogi to exclusively manage sales activities within Japan.
QUVIVIQ™, also known by its generic name daridorexant, is an innovative dual orexin receptor antagonist developed by Idorsia Pharmaceuticals. This medication aims to offer effective relief to adult patients suffering from insomnia, as indicated by its recent approval from the Ministry of Health, Labour and Welfare in Japan. With the collaboration between Nxera and Shionogi, both companies are setting the stage for a profitable market introduction.
Key Benefits of the New Partnership
Under the terms of this fresh partnership, Nxera will be responsible for supplying the drug to the Japanese market, while Shionogi will oversee all distribution and sales efforts. As part of the arrangement, Nxera will receive an upfront payment and stand to acquire royalties based on net sales through Shionogi. As production continues in Japan via Mochida’s subsidiary, the collaboration will seamlessly continue to meet market demands.
Chris Cargill, President and CEO of Nxera Pharma, emphasized the significance of QUVIVIQ™ within their product portfolio. He expressed optimism about it becoming a cornerstone of their offerings in Japan, especially considering the pressing health issue insomnia poses for many. With Shionogi’s established reach and expertise, Nxera is poised to effectively connect with healthcare professionals and patients alike, ensuring they receive timely access to this innovative treatment.
About QUVIVIQ™ and Its Mechanism of Action
QUVIVIQ™ acts by blocking orexin neuropeptides, which are responsible for promoting wakefulness, thereby helping to regulate sleep effectively. Following positive results in late-stage clinical trials in Japan, a New Drug Application for this medication was submitted in late 2023. Its efficacy in insomnia patients reflects the ongoing commitment to developing solutions for prevalent sleep disorders.
Globally, QUVIVIQ™ is already marketed in the US and Europe. Its strategic advantages stem from Nxera’s acquisition of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd., giving Nxera the rights to distribute this novel treatment throughout Japan and other regions within the APAC (excluding China).
Company Background and Expertise
Nxera Pharma has made a name for itself as a technology-driven biopharmaceutical firm. This company is focused on developing specialized medicines that address unmet medical needs within Japan and globally. With a pipeline boasting over 30 active programs across various stages of development—from discovery to late clinical stages—Nxera has positioned itself at the forefront of addressing high-demand areas within the medical sector, such as neurology, immunology, metabolic disorders, and rare diseases.
With a talented workforce of over 350 professionals, Nxera operates in several strategic locations, including Japan, the UK, Switzerland, and South Korea. The company is publicly traded on the Tokyo Stock Exchange under ticker JPX:4565.T.
Frequently Asked Questions
What is QUVIVIQ™?
QUVIVIQ™ is a dual orexin receptor antagonist designed to treat insomnia by blocking the activity of orexin neuropeptides that promote wakefulness.
What does the new partnership entail?
Nxera Pharma will supply QUVIVIQ™ in Japan, while Shionogi will handle its distribution and sales, following the termination of their previous agreement with Mochida Pharmaceutical.
When was QUVIVIQ™ approved in Japan?
The Ministry of Health, Labour and Welfare in Japan approved QUVIVIQ™ for use in treating insomnia in late September 2024.
How does Nxera Pharma plan to support QUVIVIQ™?
Nxera Pharma plans to collaborate closely with Shionogi and Mochida to prepare for the effective market launch of QUVIVIQ™ for patients affected by insomnia.
Where is Nxera Pharma based?
Nxera Pharma operates out of multiple locations, primarily in Japan, the UK, Switzerland, and South Korea. The company is publicly traded on the Tokyo Stock Exchange.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Empowering Small Businesses: 2024 and 2025 SBA Grants Insights
- Italian Manufacturing Struggles Take a Turn for the Worse
- Improving Trends in French Manufacturing Sector Amid Challenges
- Germany's Manufacturing Struggles: A Year of Decline in PMI
- LabCorp's Resilience Amidst Industry Changes and Stock Valuation
- Bangladesh's Garment Sector Faces Challenges Amid Unrest
- Deutsche Bank Predicts ECB Rate Cuts Amid Falling Inflation
- Qantas Pilots Union Declines Wage Proposal Amid Strikes
- European Markets Steady as Investors Anticipate Inflation Data
- Polydextrose Market Projected to Surpass $334 Million by 2032
Recent Articles
- ING's €2.5 Billion Share Buyback Program Progress Revealed
- Endeavour Mining Welcomes Sonia Scarselli as New EVP Exploration
- New Share Buyback Strategy Announced by PayPoint plc
- Understanding the Voting Rights of Irish Continental Group
- Mothercare PLC Seeks Temporary Trading Suspension Ahead of Results
- Investing Smart: Strong Stocks to Consider for Growth
- Overview of Irish Continental Group's Block Listing Return
- Understanding Total Voting Rights and Share Capital Overview
- Understanding Total Voting Rights at Octopus Titan VCT plc
- Understanding Total Voting Rights of Octopus AIM VCT 2 plc
- Understanding ICG Enterprise Trust plc Voting Rights Overview
- Understanding Total Voting Rights in Octopus AIM VCT plc
- Understanding Total Voting Rights for Octopus Future Generations
- Heineken's Strategic Move: Harold van den Broek Reappointment
- Caledonia Mining Corporation's Recent Securities Issuance Update
- Nxera Pharma Elevates Makoto Sugita to Chief Medical Officer
- Understanding Total Voting Rights for PayPoint Plc Stakeholders
- Getlink Welcomes Didier Cazelles as New Deputy CEO
- Strategic Partnership Enhances Cancer Research Through Data
- Malaysia's New Cloud Policy and AI Regulations Propel Growth
- TelEm Group and iBASIS Join Forces to Enhance Connectivity
- IoTech Enhances Urban Connectivity with Netmore's PaaS Solution
- Caledonia Mining Finalizes Solar Plant Agreement for Growth
- Sonia Scarselli Joins Endeavour Mining as EVP of Exploration
- ING's Remarkable Progress in Share Buyback Initiative
- Stellantis Issues Recall for 154K Jeep Plug-In Hybrids Over Fire Risks
- Transforming Industrial Operations: The Future with Treon Connect
- Transforming Operational Technology with Treon Connect
- Taiwan's Innovative Solutions in AI and Sustainable Practices
- Latest NAV Insights for Boussard & Gavaudan Holdings
- Latest Insights on Boussard & Gavaudan Holding Limited
- Understanding Sampo plc's Recent Share Buyback Strategy
- Technip Energies Achieves Performance Milestone in Vietnam
- Li Auto and XPeng Lead EV Market with Strong September Sales
- Metaplanet Inc. Expands Bitcoin Holdings, Embraces Crypto Future
- Impact of East Coast Ports Strike on Major Companies and Supply Chains
- US Stock Market Hits Record Highs Amid Powell's Remarks
- Discover the Advanced Features of Normatec Premier by Hyperice
- Partnership Between MedAire and fit2fly Redefines Passenger Health
- SK-II Launches First Flagship Store in Global Travel Market
- Menlo Security Reaches Major Revenue Milestone of $100M
- Caffewerks Unveils BaristaFlo: Affordable Espresso Machine Parts
- Havila Shipping ASA Clarifies Debt Settlement Strategy
- JCDecaux and IMC Unite for Growth in Central American Market
- LHV Group's 2024 Financial Outlook: Growth and Investment Strategy
- NORBIT ASA Launches Employee Share Purchase Initiative
- WISeKey Pioneers Semiconductor Manufacturing in Switzerland
- Technip Energies Achieves Milestone with Olefins Plant in Vietnam
- SkiStar AB Reports Growing Profits and Strong Bookings
- Santhera Reports Breakthrough LIONHEART Study Findings